Geode Capital Management LLC Has $25.86 Million Position in CareDx, Inc. $CDNA

Geode Capital Management LLC lifted its holdings in CareDx, Inc. (NASDAQ:CDNA) by 3.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,323,497 shares of the company’s stock after acquiring an additional 43,074 shares during the period. Geode Capital Management LLC’s holdings in CareDx were worth $25,864,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Sei Investments Co. increased its holdings in CareDx by 1.7% in the first quarter. Sei Investments Co. now owns 47,921 shares of the company’s stock worth $851,000 after purchasing an additional 816 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of CareDx by 3.9% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 23,925 shares of the company’s stock worth $425,000 after buying an additional 900 shares in the last quarter. MCF Advisors LLC grew its position in shares of CareDx by 292.9% during the 2nd quarter. MCF Advisors LLC now owns 1,336 shares of the company’s stock worth $26,000 after buying an additional 996 shares during the period. Cetera Trust Company N.A increased its stake in shares of CareDx by 11.2% in the 2nd quarter. Cetera Trust Company N.A now owns 12,195 shares of the company’s stock valued at $238,000 after acquiring an additional 1,225 shares in the last quarter. Finally, US Bancorp DE increased its stake in shares of CareDx by 7.2% in the 1st quarter. US Bancorp DE now owns 18,403 shares of the company’s stock valued at $327,000 after acquiring an additional 1,235 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CDNA shares. William Blair began coverage on shares of CareDx in a research note on Tuesday, August 26th. They set a “market perform” rating on the stock. Zacks Research raised shares of CareDx from a “strong sell” rating to a “hold” rating in a research report on Tuesday, November 18th. Wall Street Zen raised CareDx from a “sell” rating to a “buy” rating in a research report on Saturday, November 8th. Wells Fargo & Company dropped their price target on CareDx from $19.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of CareDx in a report on Tuesday. Four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $26.00.

CareDx Price Performance

NASDAQ:CDNA opened at $17.55 on Friday. CareDx, Inc. has a one year low of $10.96 and a one year high of $26.37. The company has a market cap of $902.65 million, a PE ratio of 17.21 and a beta of 2.50. The firm has a 50-day moving average of $15.42 and a 200-day moving average of $15.62.

CareDx (NASDAQ:CDNA) last posted its earnings results on Tuesday, November 4th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.15. The company had revenue of $100.06 million for the quarter, compared to analyst estimates of $95.25 million. CareDx had a return on equity of 18.03% and a net margin of 17.97%.The company’s revenue for the quarter was up 20.7% on a year-over-year basis. During the same quarter last year, the company earned ($0.14) earnings per share. CareDx has set its FY 2025 guidance at EPS. On average, equities research analysts expect that CareDx, Inc. will post -0.9 earnings per share for the current fiscal year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.